한미약품 '4자연합' 600억 위약벌 소송, 시니어 사업 번복 '공방'

This lawsuit exposes fundamental weaknesses in shareholder alliances within Korea's pharmaceutical sector, especially when healthcare expansion initiatives depend on third-party confirmations. The 600 billion won liquidated damages claim illustrates the substantial financial and operational risks when strategic partnerships dissolve due to unmet external dependencies—a critical governance lesson for the industry.